Aurinia Pharmaceuticals to accommodate the conference call to discuss the results of the Study Phase 1 AUR200 on June 30, 2025

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.